Sumitomo Pharma Co Ltd (TSE:4506)
円 336 -19 (-5.35%) Market Cap: 133.49 Bil Enterprise Value: 516.24 Bil PE Ratio: 0 PB Ratio: 0.85 GF Score: 49/100

Q1 2023 Sumitomo Pharma Co Ltd Earnings Call Transcript

Jul 29, 2022 / NTS GMT
Release Date Price: 円1039 (-3.71%)
Unidentified Company Representative

I would like to report on the first quarter results for FY 2022 and the current status of clinical development. Let's start with Page 3.

This slide shows a summary of our first quarter financial results. Figures are shown on the core IFRS basis. Revenues totaled JPY 159.9 billion, an increase of JPY 28.7 billion from the same period last year. Sales in Japan segment declined due to the impact of the NHI drug price revision. On the other hand, sales in North America, China and other regions segment increased due to the impact of foreign exchange translation and the recording of onetime revenues. Selling, general and administrative expenses and R&D expenses also increased due to the effect of foreign currency exchange.

Core operating profit increased JPY 4.9 billion year-on-year to JPY 13.4 billion, largely due to the increase in gross profit from higher sales. Nonrecurring items, such as changes in the fair value of contingent consideration, did not change significantly in the previous and current fiscal years.

Operating profit increased year-on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot